Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Eekman, Danielle A ^a   Bultink, Irene E M ^a   Heijboer, Annemieke C ^a   Dijkmans, Ben A C ^a,b   Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; IBANDRONIC ACID; METALLOPROTEINASE; PAMIDRONIC ACID; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; RISEDRONIC ACID; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG; UREA; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHEMOLUMINESCENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTPATIENT CARE; PATIENT COMPLIANCE; PREMENOPAUSE; RADIOIMMUNOASSAY; SPINE RADIOGRAPHY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; UREA BLOOD LEVEL; BLOOD; BONE DENSITY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 79960561478     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-167     Document Type: Article

References (19)

1. Osteoporosis. P Sambrook C Cooper, Lancet 2006 367 2010 2018 10.1016/S0140-6736(06)68891-0 16782492 (Pubitemid 43867702)
2. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. A Cranney P Tugwell J Adachi B Weaver N Zytaruk A Papaioannou,, et al. Endocr Rev 2002 23 517 523 10.1210/er.2001-3002 12202466 (Pubitemid 34925645)
3. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. A Cranney G Wells A Willan L Griffith N Zytaruk V Robinson,, et al. Endocr Rev 2002 23 508 516 10.1210/er.2001-2002 12202465 (Pubitemid 34925644)
4. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. ES Siris PL Selby KG Saag F Borgstrom RM Herings SL Silverman, Am J Med 2009 122 3 13 19962494
5. Compliance with pharmacologic therapy for osteoporosis. RA Yood S Emani JI Reed BE Lewis M Charpentier E Lydick, Osteoporos Int 2003 14 965 968 10.1007/s00198-003-1502-4 14504697 (Pubitemid 40824268)
6. What is the role of serial bone mineral density measurements in patient management? L Lenchik GM Kiebzak BA Blunt, J Clin Densitom 2002 5 Suppl 29 S38 12464709
7. Reproducibility of bone mineral density measurement in daily practice. MC Lodder WF Lems HJ Ader AE Marthinsen SC van Coeverden P Lips,, et al. Ann Rheum Dis 2004 63 285 289 10.1136/ard.2002.005678 14962964 (Pubitemid 38250672)
8. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. P Szulc PD Delmas, Osteoporos Int 2008 19 1683 1704 10.1007/s00198-008-0660-9 18629570
9. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. S Baim PD Miller, J Bone Miner Res 2009 24 561 574 10.1359/jbmr.090203 19257812
10. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. P Bergmann JJ Body S Boonen Y Boutsen JP Devogelaer S Goemaere,, et al. Int J Clin Pract 2009 63 19 26 19125989
11. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. PD Delmas B Vrijens R Eastell C Roux HA Pols JD Ringe,, et al. J Clin Endocrinol Metab 2007 92 1296 1304 10.1210/jc.2006-1526 17244788 (Pubitemid 46556401)
12. Clinical use of serum and urine bone markers in the management of osteoporosis. AK Srivastava EL Vliet EM Lewiecki M Maricic A Abdelmalek O Gluck,, et al. Curr Med Res Opin 2005 21 1015 1026 10.1185/030079905X49635 16004668 (Pubitemid 41032690)
13. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. JK Scariano PJ Garry GD Montoya JM Wilson RN Baumgartner, Clin Biochem 2001 34 639 644 10.1016/S0009-9120(01)00273-9 11849624 (Pubitemid 34159355)
14. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. SJ Glover M Gall O Schoenborn-Kellenberger M Wagener P Garnero S Boonen,, et al. J Bone Miner Res 2009 24 389 3997 10.1359/jbmr.080703 18665786
15. A cross-sectional study of bone turnover markers in healthy premenopausal women. AE de Papp HG Bone MP Caulfield R Kagan A Buinewicz E Chen,, et al. Bone 2007 40 1222 1230 (Pubitemid 46550988)
16. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas, J Bone Miner Res 2003 18 1051 1056 10.1359/jbmr.2003.18.6.1051 12817758 (Pubitemid 37294942)
17. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. N Binkley SL Silverman C Simonelli N Santiago JD Kohles G Dasic,, et al. Osteoporos Int 2009 20 1595 1601 10.1007/s00198-008-0827-4 19145396
18. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. PD Delmas F Munoz DM Black F Cosman S Boonen NB Watts,, et al. J Bone Miner Res 2009 24 1544 1551 10.1359/jbmr.090310 19338427
19. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. P Garnero R Landewe M Boers A Verhoeven LS Van Der S Christgau,, et al. Arthritis Rheum 2002 46 2847 2856 10.1002/art.10616 12428224 (Pubitemid 35315875)